| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
186.89(B) |
| Last
Volume: |
2,555,459 |
Avg
Vol: |
2,663,996 |
| 52
Week Range: |
$255.7 - $335.97 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 442 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
2,117 |
14,213 |
24,703 |
| Total Sell Value |
$0 |
$662,802 |
$3,963,214 |
$6,744,849 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
1 |
3 |
6 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bradway Robert A |
Chairman, CEO and President |
• • – |
2015-02-11 |
4 |
D |
$152.57 |
$6,185,035 |
D/D |
(40,539) |
218,102 |
|
- |
|
| Coffman Vance D |
Director |
• • – |
2015-02-06 |
4 |
D |
$153.36 |
$210,717 |
D/D |
(1,374) |
37,086 |
|
- |
|
| Coffman Vance D |
Director |
• • – |
2015-02-06 |
4 |
OE |
$42.13 |
$210,650 |
D/D |
5,000 |
38,460 |
|
- |
|
| Herringer Frank C |
Director |
• • – |
2015-02-05 |
4 |
B |
$152.29 |
$456,870 |
I/I |
3,000 |
2,000 |
2.1 |
- |
|
| Herringer Frank C |
Director |
• • – |
2015-02-05 |
4 |
D |
$151.45 |
$210,667 |
D/D |
(1,391) |
24,058 |
|
- |
|
| Herringer Frank C |
Director |
• • – |
2015-02-05 |
4 |
OE |
$42.13 |
$210,650 |
D/D |
5,000 |
25,449 |
|
- |
|
| Scott David J |
SVP, Gen. Counsel & Secy. |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,627 |
78,230 |
|
- |
|
| Tross Stuart A |
SVP, Human Resources |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,576 |
24,652 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,050 |
26,862 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
919 |
17,439 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,677 |
67,045 |
|
- |
|
| Meline David W |
EVP & CFO |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,940 |
58,537 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,597 |
118,549 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,940 |
49,585 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,677 |
35,507 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
13,398 |
196,641 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$46,714 |
D/D |
(294) |
16,520 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2015-01-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,654 |
31,830 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2015-01-28 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,654 |
47,755 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$143,637 |
D/D |
(904) |
33,484 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$153,011 |
D/D |
(963) |
45,645 |
|
- |
|
| Scott David J |
SVP, Gen. Counsel & Secy. |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$103,120 |
D/D |
(649) |
75,583 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$85,483 |
D/D |
(538) |
63,368 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$152,376 |
D/D |
(959) |
113,952 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$384,196 |
D/D |
(2,418) |
183,243 |
|
- |
|
2210 Records found
|
|
Page 37 of 89 |
|
|
6.24 (1.99%) 
